BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF, TSX: IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, is pleased to announce that Jeff Morhet, Chairman and CEO, will be a guest speaker on BNN – Business News Network’s Power Breakfast segment, which highlights top officials of important and powerful companies in Canadian and U.S. business.
